Atreca, Inc. is a biopharmaceutical company that develops immunotherapeutics for solid tumors, including its lead product ATRC-101, a novel monoclonal antibody with a unique mechanism of action. ATRC-101 targets a variety of cancers and has shown promise in multiple patient samples. The company is also working on additional therapies, such as a tyrosine kinase and a malaria treatment.